OPM 201
Alternative Names: OPM-201; S-221237Latest Information Update: 26 Dec 2024
Price :
$50 *
At a glance
- Originator Oncodesign Biotechnology
- Developer Servier
- Class Antiparkinsonians; Macrocyclic compounds; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 20 Dec 2024 Oncodesign Precision Medicine reacquires the OPM 201 program for Parkinson’s disease from Servier Laboratories
- 20 Dec 2024 Adverse events data from a phase I trial in Parkinson's disease released by Oncodesign Precision Medicine
- 20 Dec 2024 Oncodesign Biotechnology completes a phase I trial in Parkinson's disease (In Volunteers) in France, prior to December 2024